Edition:
United Kingdom

People: Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

2.23USD
15 Jul 2019
Change (% chg)

$0.05 (+2.29%)
Prev Close
$2.18
Open
$2.20
Day's High
$2.28
Day's Low
$2.12
Volume
96,367
Avg. Vol
194,929
52-wk High
$20.80
52-wk Low
$1.93

Ruffo, Frank 

Mr. Frank Ruffo CPA is Co-Founder, Chief Financial Officer of the Company since July 2012. From January 2014 to December 2015, Mr. Ruffo served part-time as a financial consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Mr. Ruffo also served part-time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining our company, Mr. Ruffo co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Prior to joining Vicept Therapeutics, Inc., from 1996 to 2008, Mr. Ruffo served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. He is a certified public accountant in Pennsylvania (inactive since 2008). Mr. Ruffo received his B.S. degree in business administration with a major in accounting from LaSalle University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Neal Walker

4,363,390

Frank Ruffo

--

Stuart Shanler

1,808,440

Kamil Ali-Jackson

2,725,200

David Gordon

2,116,180

Maxine Gowen

--
As Of  31 Dec 2018